The Nebrasksa-based MRI medical device company has developed and is distributing a FDA trifecta-cleared, AI-driven medical software called ProstatID™
Bot Image introduces ProstatID and bpMRI. (Credit: Michal Jarmoluk from Pixabay)
Prostate cancer management reached a new pinnacle of precision with Bot Image’s ProstatID using Bi-parametric MRI (bpMRI). The Nebrasksa-based MRI medical device company has developed and is distributing a FDA trifecta-cleared, AI-driven medical software called ProstatID™ ushering in a new era of early accurate detection and care, offering a host of merits that will redefine prostate cancer screening, detection, diagnosis and management.
The foremost advantage of Bot Image’s ProstatID, in conjunction with bpMRI, is the ability to detect prostate cancer at its earliest stages with unmatched accuracy. ProstatID’s state-of-the-art technology, combined with bpMRI’s comprehensive imaging, ensures that even the tiniest anomalies are identified. This means earlier detection, timely intervention, and improved treatment outcomes.
ProstatID and bpMRI work in harmony to guide physicians with pinpoint accuracy to the areas that require biopsy. No more uncertain blind biopsies. This not only reduces discomfort for patients but also leads to more reliable diagnostic results.
Prostate cancer varies from person to person, and ProstatID recognizes this individuality. It allows healthcare providers to create tailored treatment plans that align with each patient’s unique cancer characteristics. This personalized approach maximizes treatment effectiveness while minimizing side effects and preserving quality of life.
The risk of overtreatment has long been a concern in prostate cancer care. ProstatID and bpMRI help differentiate between aggressive and indolent tumors. This ensures that patients receive treatments that match the actual threat to their health, reducing unnecessary surgeries and their associated risks.
For those undergoing prostate cancer treatment, monitoring progress is essential. ProstatID in conjunction with bpMRI offers a safe, radiation-free method for assessing treatment response. Regular imaging ensures timely adjustments to treatment plans, optimizing outcomes.
Patient comfort and well-being are at the core of Bot Image’s approach. ProstatID and bpMRI offer a non-invasive, radiation-free imaging solution. The process is quick, comfortable, and designed with focus on the patient’s peace of mind.
Source: Company Press Release